Jeffrey Lancet, MD, discusses the findings from a phase III trial of CPX-351 versus 7+3 in older patients with high-risk, secondary acute myeloid leukemia
CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?
Recent Articles
R-CHOP Versus R-EPOCH: No Difference in Survival for Patients With MYC-Rearranged, Double- or Triple-Hit...
Overall survival (OS) outcomes were similar between patients with MYC-rearranged diffuse large B-cell lymphoma (DLBCL) and double-hit lymphoma (DHL)/triple-hit lymphoma (THL) who were treated...
Investigators Identify Distinct Molecular Subgroups to Guide Treatment Decisions in AML
Analyzing genetic data from more than 3,000 patients with acute myeloid leukemia (AML), researchers from Memorial Sloan Kettering Cancer Center identified 14 distinct molecular...
Evaluating Enasidenib, With or Without Azacitidine, in Patients with IDH2-Mutated MDS
Enasidenib was had a tolerable safety profile and showed promising clinical activity in patients with IDH2-mutated, high-risk myelodysplastic syndromes (MDS), according to results from...
Masking, Vaccination, and Research Needed to Protect Our Most Vulnerable Against COVID-19
This article is republished from a President’s Column that originally appeared in the July/August 2021 issue of The Hematologist.
In mid-May, the Centers for Disease...
Fixed-Duration Ibrutinib, Venetoclax Oral Combination Effective in CLL/SLL
A fixed-duration regimen of first-line ibrutinib plus venetoclax provided deep, durable responses in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to...
Current Issue
June 2021 Volume 7 Issue 7
This issue reviews the management and prevention of peripheral neuropathy, early successes of SCD screening programs in sub-Saharan Africa, and more.